1635P Clinical and pathologic prognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) in patients (pts) with advanced gastrointestinal stromal tumor (GIST)

Abstract

Several retrospective studies have demonstrated the efficacy of residual lesion surgery in pts with advanced GIST responding to IM. However, to date, no studies have comprehensively evaluated the prognostic factors, especially pathologic factors, for the efficacy of residual lesion surgery.